2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Colorectal Neoplasms
34
Carcinoma, Non-Small-Cell Lung
26
Breast Neoplasms
26
Lung Neoplasms
24
Colonic Neoplasms
18
Head and Neck Neoplasms
16
Rectal Neoplasms
14
Prostatic Neoplasms
11
Sarcoma
10
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Neoplasms
7
Mouth Neoplasms
7
Melanoma
7
Esophageal Neoplasms
7
Adenomatous Polyposis Coli
7
Ovarian Neoplasms
6
Glioblastoma
6
Precancerous Conditions
5
Neuroblastoma
5
Liver Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Oropharyngeal Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
trametinib
3
fludarabine
3
dabrafenib
3
Tacrolimus
3
Melphalan
3
Cyclophosphamide
3
Busulfan
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
erdafitinib
2
ensartinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Rituximab
2
Mycophenolic Acid
2
LY3023414
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Celecoxib
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled